283 results on '"Hassoun H."'
Search Results
2. Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study
3. S177: EVALUATING SERUM FREE LIGHT CHAIN RATIO AS A BIOMARKER FOR MULTIPLE MYELOMA
4. P886: AFRICAN AMERICAN PATIENTS WITH SMOLDERING MULTIPLE MYELOMA MAY HAVE A LOWER RISK OF PROGRESSION COMPARED TO WHITE PATIENTS
5. Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis
6. HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in 55 Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD)-Subgroup Analysis
7. HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup Analysis
8. HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients With Relapsed/Refractory Multiple Myeloma With Extramedullary Disease-Subgroup Analysis
9. Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studies
10. Melflufen Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Exposed and/or Refractory to Prior Alkylators - A Pooled Analysis of the O-12-M1 and HORIZON Studies
11. Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center
12. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis
13. Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients’ monitoring after transplantation
14. A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma
15. Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance
16. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease
17. Melflufen for relapsed and refractory multiple myeloma
18. HORIZON (OP-106): Melflufen Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody - Primary and Subgroup Analysis
19. Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation
20. Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial
21. Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects
22. Impairment of Alveolar Gas Exchange Caused by Lamp Oil Aspiration Quantified in A Physical Model: P79 (EI0153)
23. Risk-Adapted Melphalan with Stem Cell Transplant (Sct) and Adjuvant Dexamethasone (Dex) +/- Thalidomide (Thal) Achieves Low Treatmentrelated Mortality and High Hematologic Response Rates
24. CD32B Expression Reflects Intraclonal Functional Heterogeity in Multiple Myeloma: B500
25. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone
26. Updated Efficacy and Safety of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma Refractory to Daratumumab and/or Pomalidomide: HORIZON (OP-106)
27. Melflufen in patients (pts) with relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab (dara) and/or pomalidomide (pom) (OP-106)
28. Specific Enteral Nutrients Alter Mucosal Blood Flow During Gut Ischemia/Reperfusion.: 0039
29. S1605 HORIZON (OP-106): UPDATED EFFICACY AND SAFETY OF MELFLUFEN IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO DARATUMUMAB (DARA) AND/OR POMALIDOMIDE (POM)
30. Immunocytochemical analysis of valproic acid induced histone H3 and H4 acetylation during differentiation of rat adipose derived stem cells into neuron-like cells
31. Validación de la Escala de Esperanza en Enfermedad Terminal para familiares breve (EEET-fb). Análisis de validez y fiabilidad
32. Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis
33. Haemangioblastoma of the brain: Computed tomography and angiographic studies in 17 patients
34. CD34-selected allogeneic hematopoietic stem cell transplantation for patients with relapsed, high-risk multiple myeloma
35. Analysis of Second Primary Malignancies (SPMs) in CALGB (Alliance)/ECOG/BMT CTN 100104
36. A Response Adapted Approach to Induction Treatment Yields acceptable Outcome in Patients with Multiple Myeloma (MM) undergoing Autologous Stem Cell transplantation (ASCT)
37. Catalog of total excitation–emission and total synchronous fluorescence maps with synchronous fluorescence spectra of homologated fluorescent pesticides in large use in Morocco: development of a spectrometric low cost and direct analysis as an alert method in case of massive contamination of soils and waters by fluorescent pesticides
38. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis
39. A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma
40. Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients’ monitoring after transplantation
41. Maintained Hematologic and Organ Responses Following Risk Adapted Stem Cell Transplant (SCT) in Systemic Light-Chain Amyloidosis (AL) Using Bortezomib and Dexamethasone as Consolidation Therapy
42. Outcomes Following Salvage Autologous Stem Cell Transplant (Sct) for Multiple Myeloma
43. Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis
44. A Pilot Study of T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation With Busulfan, Melphalan, and Fludarabine Conditioning Followed by Post Transplantation Donor Lymphocyte Infusions for Patients With Relapsed Multiple Myeloma and High-Risk Cytogenetics
45. Adjuvant bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in patients with light-chain amyloidosis (AL)
46. FDG PET/CT (FDG PET) in evaluation of response in patients with multiple myeloma (MM) treated with bortezomib, pegylated liposomal doxorubicin, and dexamethasone
47. B500 CD32B Expression Reflects Intraclonal Functional Heterogeity in Multiple Myeloma
48. Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma
49. Catalog of total excitation-emission and total synchronous fluorescence maps with synchronous fluorescence spectra of homologated fluorescent pesticides in large use in Morocco: development of a spectrometric low cost and direct analysis as an alert method in case of massive contamination of soils and waters by fluorescent pesticides
50. Single-agent bortezomib in previously untreated multiple myeloma (MM): Results of a phase II multicenter study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.